AR054245A1 - Oblea que contiene hormonas esteroides - Google Patents
Oblea que contiene hormonas esteroidesInfo
- Publication number
- AR054245A1 AR054245A1 AR20060101273A ARP060101273A AR054245A1 AR 054245 A1 AR054245 A1 AR 054245A1 AR 20060101273 A AR20060101273 A AR 20060101273A AR P060101273 A ARP060101273 A AR P060101273A AR 054245 A1 AR054245 A1 AR 054245A1
- Authority
- AR
- Argentina
- Prior art keywords
- application system
- steroid hormone
- steroid
- fluocortolone
- ment
- Prior art date
Links
- 239000003270 steroid hormone Substances 0.000 title abstract 9
- 241000604231 Oblea Species 0.000 title 1
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 abstract 2
- 108010010803 Gelatin Proteins 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 229960001145 deflazacort Drugs 0.000 abstract 2
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 abstract 2
- 229960003973 fluocortolone Drugs 0.000 abstract 2
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 abstract 2
- 229920000159 gelatin Polymers 0.000 abstract 2
- 239000008273 gelatin Substances 0.000 abstract 2
- 235000019322 gelatine Nutrition 0.000 abstract 2
- 235000011852 gelatine desserts Nutrition 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 210000000214 mouth Anatomy 0.000 abstract 2
- 229960004719 nandrolone Drugs 0.000 abstract 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- 229920000881 Modified starch Polymers 0.000 abstract 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 abstract 1
- 229960003473 androstanolone Drugs 0.000 abstract 1
- 229960005471 androstenedione Drugs 0.000 abstract 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 abstract 1
- 229960000978 cyproterone acetate Drugs 0.000 abstract 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229960002568 ethinylestradiol Drugs 0.000 abstract 1
- XZBJVIQXJHGUBE-HZMVJJPJSA-N fluocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O XZBJVIQXJHGUBE-HZMVJJPJSA-N 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 229960001067 hydrocortisone acetate Drugs 0.000 abstract 1
- 229960004400 levonorgestrel Drugs 0.000 abstract 1
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 abstract 1
- 229960005272 mesterolone Drugs 0.000 abstract 1
- 229960003578 metenolone Drugs 0.000 abstract 1
- ANJQEDFWRSLVBR-VHUDCFPWSA-N methenolone Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C ANJQEDFWRSLVBR-VHUDCFPWSA-N 0.000 abstract 1
- 229960002037 methylprednisolone aceponate Drugs 0.000 abstract 1
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000019426 modified starch Nutrition 0.000 abstract 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 abstract 1
- 229960000464 oxandrolone Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 abstract 1
- 229960005205 prednisolone Drugs 0.000 abstract 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- -1 signodene Chemical compound 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005015128A DE102005015128B4 (de) | 2005-03-31 | 2005-03-31 | Wafer enthaltend Steroidhormone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054245A1 true AR054245A1 (es) | 2007-06-13 |
Family
ID=36998911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20060101273A AR054245A1 (es) | 2005-03-31 | 2006-03-31 | Oblea que contiene hormonas esteroides |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9763960B2 (enExample) |
| EP (1) | EP1863444B1 (enExample) |
| JP (2) | JP5843416B2 (enExample) |
| KR (2) | KR101428625B1 (enExample) |
| CN (2) | CN104983669B (enExample) |
| AR (1) | AR054245A1 (enExample) |
| AU (1) | AU2006228820B2 (enExample) |
| BR (1) | BRPI0609601A2 (enExample) |
| CA (1) | CA2598892C (enExample) |
| CR (1) | CR9468A (enExample) |
| DE (1) | DE102005015128B4 (enExample) |
| DO (1) | DOP2006000070A (enExample) |
| EA (1) | EA014183B1 (enExample) |
| GT (1) | GT200600126A (enExample) |
| IL (1) | IL186081A0 (enExample) |
| MX (1) | MX2007012081A (enExample) |
| NO (1) | NO20075404L (enExample) |
| NZ (1) | NZ592882A (enExample) |
| PE (1) | PE20061194A1 (enExample) |
| SG (1) | SG179459A1 (enExample) |
| SV (1) | SV2008002466A (enExample) |
| TW (1) | TWI393576B (enExample) |
| UA (1) | UA92011C2 (enExample) |
| UY (1) | UY29441A1 (enExample) |
| WO (1) | WO2006102990A2 (enExample) |
| ZA (1) | ZA200706116B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2985026T3 (pl) | 2005-04-15 | 2023-02-20 | Clarus Therapeutics, Inc. | Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| DE102006027796A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Estrogen-Gestagen-Kombinationen |
| EA018330B1 (ru) * | 2008-02-13 | 2013-07-30 | Байер Интеллекчуал Проперти Гмбх | Система доставки лекарственного средства со стабилизирующим эффектом |
| MX2010008940A (es) * | 2008-02-13 | 2010-10-05 | Bayer Schering Pharma Ag | Sistemas de administracion de drogas que contienen estradiol. |
| TW201008569A (en) * | 2008-08-08 | 2010-03-01 | Bayer Schering Pharma Ag | Progestin-containing drug delivery system |
| CA2744127A1 (en) * | 2008-11-21 | 2010-05-27 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system |
| CN102933207B (zh) | 2009-10-30 | 2018-02-02 | Ix生物医药有限公司 | 快速溶解固体剂型 |
| US12186426B2 (en) | 2009-10-30 | 2025-01-07 | Ix Biopharma Ltd. | Solid dosage form |
| US10806703B2 (en) * | 2012-01-20 | 2020-10-20 | Lts Lohmann Therapie-System Ag | Transmucosal administration system for a pharmaceutical drug |
| CA2878680C (en) | 2012-07-23 | 2019-09-17 | Crayola, Llc | Dissolvable films and methods of using the same |
| DE102017112527B4 (de) * | 2017-06-07 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | Schnell zerfallende Schaumwafer mit hohem Flächengewicht |
| HUE072803T2 (hu) * | 2018-02-02 | 2025-12-28 | Acerus Biopharma Inc | Tesztoszteron terápiás eljárások |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB981372A (en) * | 1960-05-04 | 1965-01-27 | Pfizer Ltd | Pharmaceutical formulations for oral administration to animals |
| US4136162A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
| DK0641192T3 (da) * | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Anordning til transmucosal lægemiddelafgivelse |
| DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| DE19847252B4 (de) * | 1998-10-02 | 2004-02-12 | Jenapharm Gmbh & Co. Kg | Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron |
| US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20030092658A1 (en) * | 2001-02-02 | 2003-05-15 | Meyers Rachel E. | Novel human enzyme family members and uses thereof |
| JP2004502724A (ja) * | 2000-07-06 | 2004-01-29 | デルシス ファーマシューティカル コーポレイション | 増大した安定性を有するヘルスケア製品の製剤化方法 |
| GB0100760D0 (en) * | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| US6585997B2 (en) * | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| FR2832311B1 (fr) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
| JO2492B1 (en) * | 2003-04-28 | 2009-10-05 | شيرينج ايه جي | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients |
| JP2007500729A (ja) * | 2003-07-31 | 2007-01-18 | アイバックス コーポレイション | 雄性及び雌性の性機能障害の治療方法 |
| AU2004283431B2 (en) * | 2003-10-10 | 2009-09-10 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
-
2005
- 2005-03-31 DE DE102005015128A patent/DE102005015128B4/de not_active Expired - Fee Related
-
2006
- 2006-03-13 TW TW095108474A patent/TWI393576B/zh not_active IP Right Cessation
- 2006-03-15 WO PCT/EP2006/002358 patent/WO2006102990A2/de not_active Ceased
- 2006-03-15 EA EA200702102A patent/EA014183B1/ru not_active IP Right Cessation
- 2006-03-15 KR KR1020077022368A patent/KR101428625B1/ko not_active Expired - Fee Related
- 2006-03-15 UA UAA200712054A patent/UA92011C2/ru unknown
- 2006-03-15 EP EP06723435.1A patent/EP1863444B1/de active Active
- 2006-03-15 AU AU2006228820A patent/AU2006228820B2/en not_active Ceased
- 2006-03-15 CA CA2598892A patent/CA2598892C/en active Active
- 2006-03-15 BR BRPI0609601-8A patent/BRPI0609601A2/pt not_active Application Discontinuation
- 2006-03-15 NZ NZ592882A patent/NZ592882A/xx not_active IP Right Cessation
- 2006-03-15 KR KR1020147008056A patent/KR20140063740A/ko not_active Ceased
- 2006-03-15 MX MX2007012081A patent/MX2007012081A/es active IP Right Grant
- 2006-03-15 SG SG2012016937A patent/SG179459A1/en unknown
- 2006-03-15 CN CN201510393577.8A patent/CN104983669B/zh active Active
- 2006-03-15 CN CNA2006800071551A patent/CN101132766A/zh active Pending
- 2006-03-15 JP JP2008503397A patent/JP5843416B2/ja not_active Expired - Fee Related
- 2006-03-27 SV SV2006002466A patent/SV2008002466A/es not_active Application Discontinuation
- 2006-03-27 GT GT200600126A patent/GT200600126A/es unknown
- 2006-03-27 PE PE2006000341A patent/PE20061194A1/es not_active Application Discontinuation
- 2006-03-27 UY UY29441A patent/UY29441A1/es not_active Application Discontinuation
- 2006-03-27 DO DO2006000070A patent/DOP2006000070A/es unknown
- 2006-03-28 US US11/391,646 patent/US9763960B2/en not_active Expired - Fee Related
- 2006-03-31 AR AR20060101273A patent/AR054245A1/es not_active Application Discontinuation
-
2007
- 2007-07-24 ZA ZA200706116A patent/ZA200706116B/xx unknown
- 2007-09-19 IL IL186081A patent/IL186081A0/en unknown
- 2007-10-23 CR CR9468A patent/CR9468A/es unknown
- 2007-10-24 NO NO20075404A patent/NO20075404L/no not_active Application Discontinuation
-
2013
- 2013-04-18 JP JP2013087238A patent/JP2013155190A/ja active Pending
-
2017
- 2017-08-23 US US15/684,245 patent/US20170348321A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054245A1 (es) | Oblea que contiene hormonas esteroides | |
| Africander et al. | Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception | |
| AU2015221447B2 (en) | Methods and compositions for treating cancer | |
| Sitruk-Ware | Pharmacology of different progestogens: the special case of drospirenone | |
| Sitruk-Ware | New progestagens for contraceptive use | |
| Pugeat et al. | Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma | |
| HRP20090614T1 (hr) | Stabilizirane superzasićene krute otopine steroidnih lijekova | |
| Schindler | The “newer” progestogens and postmenopausal hormone therapy (HRT) | |
| CN100391462C (zh) | 增强的透皮给药系统 | |
| Schindler et al. | Reprint of classification and pharmacology of progestins | |
| Vernon et al. | Observations on the binding of androgens by rat testis seminiferous tubules and testis extracts | |
| JP2011502172A5 (enExample) | ||
| KR970069031A (ko) | 당 제피로부터 스테로이드의 방출이 조절되는 약제학적 정제 | |
| JP2007528389A5 (enExample) | ||
| US20150290221A1 (en) | Methods and compositions for treating cancer | |
| KR20100094495A (ko) | 호르몬 및 스테로이드를 위한 경피 전달 시스템 | |
| WO2014178065A1 (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
| CA2467237A1 (en) | Method of preventing or treating benign gynaecological disorders | |
| RU2009102772A (ru) | 18-метил-19-норандрост-4-ен-17, 17-спироэфир (18-метил-19-нор-20-спирокс-4-ен-3-он) и фармацевтические препараты, которые его содержат | |
| JP2008534533A5 (enExample) | ||
| Gompel et al. | Tibolone actions on normal and breast cancer cells | |
| WO2000047603A3 (de) | 16-hydroxyestratriene als selektiv wirksame estrogene | |
| Ruan et al. | Optimizing menopausal hormone therapy: for treatment and prevention, menstrual regulation, and reduction of possible risks | |
| US20160346298A1 (en) | Hormone delivery system and method | |
| TN2010000007A1 (en) | 8-beta- substituted estratrienes as selectively active estrogens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |